Ascentage Pharma Group International (AAPG) stock
AAPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 29, 2026Score 3/30
$13.01−0.13 (-0.97%)
Close on Nov 18, 2026Market cap $1.21BP/E –Yield –
Ascentage Pharma Group International r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was CN¥1.14B, up 20.1% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | CN¥1.14B | +20.1% |
| FY2024 | Dec 31, 2024 | CN¥947.25M | +34.0% |
| FY2023 | Dec 31, 2023 | CN¥706.97M | -4.9% |
| FY2022 | Dec 31, 2022 | CN¥743.10M | – |
See a number that looks wrong?